Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01, Briefing.com reports. During the same period last year, the firm earned ($0.73) earnings per share.
Xenon Pharmaceuticals Trading Down 3.3 %
Shares of NASDAQ XENE traded down $1.42 during midday trading on Wednesday, reaching $41.97. 476,514 shares of the stock were exchanged, compared to its average volume of 386,113. The stock has a 50 day moving average price of $41.11 and a 200-day moving average price of $40.34. The company has a market capitalization of $3.18 billion, a P/E ratio of -14.88 and a beta of 1.25. Xenon Pharmaceuticals has a 52-week low of $28.10 and a 52-week high of $50.99.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Royal Bank of Canada restated an "outperform" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. HC Wainwright reiterated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday. Raymond James restated an "outperform" rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $57.45.
Get Our Latest Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
